What You Should Know:
- Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catalio Capital Management. Formerly known as Clover Therapeutics, the company’s data-driven approach integrates genomics, deep phenotyping and machine learning for target and biomarker discovery.
- The company will use the funding to advance the frontiers of
Read More
Biomarker Discovery
Medidata, Labcorp Partner to Expand Decentralized Clinical Trials for Digital Biomarker Discovery
What You Should Know:
- Medidata, a Dassault Systèmes company, today announced a first-of-its-kind partnership with Labcorp using the Medidata Sensor Cloud to introduce a new model to advance the use of medical-grade sensors in clinical trials and accelerate biomarker discovery.
- As part of the partnership, Medidata will receive and process medical-grade sensor data within drug, vaccine and device trials across Labcorp Drug Development’s clinical trial portfolio,
Read More
Medidata Acquires Digital Biomarker Business of MC10 / Clinical Trials & Wearable Sensors
What You Should Know:
- Clinical trials technology company Medidata has
acquired the digital biomarker business of MC10.
- MC10’s offerings will bring novel clinical analytics
and biosensor capabilities to Medidata’s existing technology solutions,
enhancing Medidata’s capabilities to integrate data from wearable sensors –
including clinical grade metrics – in clinical trials.
- With this acquisition, Medidata’s integrated offering
will help provide life sciences companies and device
Read More
Paige Lands Additional $20M for AI-Native Digital Pathology Ecosystem
What You Should Know:
- Paige secures an additional $15M from Goldman Sachs totaling $20M to close out a total Series B funding round of $70M for its AI-native digital pathology ecosystem.
- The company’s continued product portfolio of innovation in telepathology and digital diagnostics accelerated by further investment.
Paige, an NYC-based leader in computational pathology transforming the diagnosis and treatment of cancer, today announced it received an additional $15M from
Read More
Analysis: Applying AI in the Fight Against The Coronavirus
Drug discovery is a notoriously long, complex and expensive process requiring the concerted efforts of the world’s brightest minds. The complexity in understanding human physiology and molecular mechanisms is increasing with every new research paper published and for every new compound tested. As the world is facing a new challenge in trying to both adapt to and defend itself against the coronavirus, artificial intelligence is offering new hope that a cure might be developed faster than ever
Read More
Paige Raises $45M to Expand AI-Native Digital Pathology Ecosystem to Accelerate Biomarker Discovery
- Paige raises $45M in Series B funding led by Healthcare Venture Partners with participation from Breyer Capital, Kenan Turnacioglu, and others. - The funding will be used to accelerate commercial efforts of its AI-native digital pathology ecosystem in the U.S., Europe, Brazil, and Canada. Paige, a NYC-based leader in computational pathology transforming the diagnosis and treatment of cancer, today announced it has closed its Series B funding round of $45 million, bringing the Company’s
Read More
ICON Acquires Precision Medicine for Oncology Company MolecularMD
ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More
Genetic Material Once Considered Junk Actually Could Hold Key to Cancer Drug Response
Material left out of common processes for sequencing genetic material in cancer tumors may actually carry important information about why only some people respond to immunotherapy, possibly offering better insight than the type of material that is being sequenced, according to a study by Mount Sinai researchers published on April 3 in Cell Reports. Sequencing a type of genetic material in cancer tumors called messenger RNA has transformed personalized cancer therapy and revealed biomarkers for
Read More
Gore Innovation Center, Kenzen Team Up to Develop Dermal Biometrics Patch
The Gore Innovation Center in Silicon Valley, today announced a joint development agreement and cash investment in digital health startup, Kenzen. W. L. Gore & Associates (Gore) engineers and scientists will work hand in hand with Kenzen, an innovator in precision health monitoring and insights, to develop a comprehensive wearable health monitoring system that employs biosensor data and predictive modeling to anticipate and prevent avoidable injuries and health conditions.By integrating
Read More
Philips Launches Informatics Platform to Advance Drug Research & Biomarker Discovery
Today, Philips has announced the launch of Xplore, a web-based image and data management platform that will help pharma and academic researchers speed up drug research and biomarker discovery through enhanced integration, visualization and analytics tools. Xplore v4.0 will be available commercially in July 2017. Customers have the option to purchase the basic package or with custom additions including a dedicated TMA module for enabling faster and streamlined research.As the industry continues
Read More
